香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的全部內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 （於開曼群島註冊成立的有限公司） （股份代號：6855） 根據2022年受限制股份單位計劃進一步授出獎勵；及 根據首次公開發售後購股權計劃授出購股權 茲提述(i)亞盛醫藥集團（「本公司」，連同其附屬公司統稱「本集團」）日期為2021 年2月2日、2022年6月23日及2022年7月14日的公告（「該等公告」）；(ii)本公司日 期為2025年4月30日的通函（「該通函」）；及(iii)本公司日期為2025年5月19日的投 票結果公告，內容有關（其中包括）採納2022年受限制股份單位計劃及修訂2022年 受限制股份單位計劃，以及採納首次公開發售後購股權計劃及修訂首次公開發售 後購股權計劃。除另有界定者外，本公告所用詞彙與該等公告及該通函所界定者 具有相同涵義。 根據2022年受限制股份單位計劃進一步授出獎勵 董事會宣 ...

Group 1 - The stock of Ascentage Pharma-B (06855.HK) increased by over 3%, specifically by 3.04%, reaching a price of 64.35 HKD [1] - The trading volume for Ascentage Pharma-B was 46.0484 million HKD at the time of reporting [1]

Core Viewpoint - Ascentage Pharma-B (06855) saw a rise of over 3%, currently trading at HKD 64.35 with a transaction volume of HKD 46.0484 million, following the announcement of positive clinical trial results for its novel drug Olverembatinib (brand name: Nairike) in treating gastrointestinal stromal tumors (GIST) [1] Group 1: Clinical Trial Results - On November 25, Ascentage Pharma announced that the research results of its original Class 1 new drug Olverembatinib for GIST were published in the prestigious journal Signal Transduction and Targeted Therapy, which has an impact factor of 52.7 [1] - The study demonstrated that Olverembatinib shows good efficacy and safety in SDH-deficient GIST, revealing a novel mechanism of anti-tumor action through lipid metabolism regulation [1] - The Phase I study evaluated the safety and anti-tumor activity of Olverembatinib in 66 patients with unresectable/metastatic GIST and other solid tumors, including 26 patients with SDH-deficient GIST who had failed prior treatment with tyrosine kinase inhibitors (TKIs) [1] Group 2: Significance of the Study - This is the largest prospective clinical trial conducted to date for this rare subtype of GIST [1]

Core Viewpoint - Ascentage Pharma-B (06855) saw a stock increase of over 3%, currently trading at HKD 64.35 with a transaction volume of HKD 46.048 million, following the announcement of positive clinical trial results for its novel drug Olarebactam (brand name: Nairike) in treating gastrointestinal stromal tumors (GIST) [1] Group 1: Clinical Trial Results - Ascentage Pharma announced the successful publication of research results for Olarebactam in the international journal "Signal Transduction and Targeted Therapy," which has an impact factor of 52.7 [1] - The study demonstrated that Olarebactam shows good efficacy and safety in treating SDH-deficient GIST, revealing a novel mechanism of action through lipid metabolism regulation [1] - The Phase I trial evaluated the safety and anti-tumor activity of Olarebactam in 66 patients with unresectable/metastatic GIST and other solid tumors, including 26 patients with SDH-deficient GIST who had failed prior treatment with tyrosine kinase inhibitors (TKIs) [1] - This trial is noted as the largest prospective clinical study to date targeting this rare subtype of GIST [1]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the development paths of innovative drugs and the role of AI in drug research and development [1][2] - Industry experts emphasized the need for Chinese pharmaceutical companies to shift from "follower" to "leader" by addressing unmet medical needs and leveraging innovative technologies [1][2] Group 1: Conference Highlights - The conference theme was "Bay Area Innovation, Navigating New Journeys," discussing key topics such as dual circulation development, accelerated technology transfer, and compliance in global expansion [1] - Notable speakers included industry leaders and experts, highlighting the importance of innovation and internationalization as core drivers for Chinese pharmaceutical companies [2] Group 2: Regulatory and Industry Perspectives - The Director of the Guangdong Provincial Drug Administration stressed the importance of drug quality and safety, urging companies to strengthen regulatory compliance and communication with authorities to avoid approval delays [1] - The conference aimed to inject new vitality into the biopharmaceutical industry in the Greater Bay Area and across China, promoting high-quality development and attracting talent and projects [1]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the theme "Bay Area Innovation, Navigating New Journeys" [1] - Key topics discussed included the dual circulation development path for innovative drugs, acceleration of technology transfer, compliant global expansion, and the role of AI in empowering the entire drug development chain [1] Group 1 - The conference was co-hosted by the Guangdong Provincial Biopharmaceutical Innovation Technology Association and the Guangzhou Science and Technology Progress Foundation, with participation from various organizations including Boji Pharmaceutical Technology Co., Ltd. [1] - The event aimed to explore solutions for innovative drugs in the current complex environment, injecting new vitality and wisdom into the innovation development of the biopharmaceutical industry in the Greater Bay Area and nationwide [1] Group 2 - Notable attendees included prominent figures such as academician Zhong Nanshan, various directors from health authorities in Guangdong, Hong Kong, and Macau, and leaders from over 1,000 top scientists and industry leaders [2] - The conference provided a platform for discussing the future development and innovative practices in the biopharmaceutical sector within the Greater Bay Area [2]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has gained 1.2% with a trading volume of 351 million yuan and a total fund size of 2.079 billion yuan as of November 10 [1] - Key performing stocks within the ETF include InnoCare Pharma-B, Bionet, and Ascletis Pharma, with respective gains of 5.4%, 4.43%, and 4.37% [1] - Conversely, stocks such as Kangzhe Pharmaceutical, MIRXES-B, and Innovent Biologics showed weaker performance, with declines of 1.28%, 0.94%, and 0.65% respectively [1] Group 2 - The innovative drug sector is identified as the largest investment opportunity in the pharmaceutical sector for 2025, with a focus on dual/multi-target drugs, chronic disease medications addressing unmet clinical needs, and ADCs [2] - There is a noted improvement in domestic and international innovative drug financing data, with an upward trend in CXO industry orders, indicating a potential recovery in valuations and performance [2] - The medical device sector is experiencing accelerated approvals for innovative products, such as the approval of the chest and abdominal aortic stent system by Xianjian Technology, which is expected to enhance long-term profit margins [2] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF and its linked funds passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with the top ten weighted stocks including BeiGene, China Biologic Products, and Innovent Biologics [3]

Core Insights - The article discusses the recent financial performance of a leading company in the technology sector, highlighting a significant increase in revenue and net income compared to the previous year [1] Financial Performance - The company reported a revenue of $10 billion, representing a 20% increase year-over-year [1] - Net income reached $2 billion, which is a 25% increase from the last fiscal year [1] - Earnings per share (EPS) rose to $5, up from $4 in the previous year, indicating a 25% growth [1] Market Position - The company has strengthened its market position, capturing an additional 5% market share in the last quarter [1] - The technology sector overall is experiencing robust growth, with a projected annual growth rate of 15% over the next five years [1] Strategic Initiatives - The company has launched several new products that contributed to the revenue growth, with one product alone accounting for $1 billion in sales [1] - Investments in research and development have increased by 30%, reflecting the company's commitment to innovation [1] Future Outlook - Analysts predict continued growth for the company, with expected revenue of $12 billion next year, marking a 20% increase [1] - The company plans to expand into new international markets, which could further enhance its growth trajectory [1]

公司名稱: 亞盛醫藥集團 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06855 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | | --- | | 2025年10月31日 | | 狀態: | | 新提交 | 致：香港交易及結算所有限公司 本月底法定/註冊股本 ...

Core Insights - The company has announced multiple clinical and preclinical advancements for three products (Nailike®, Lishengtuo®, APG-5918) selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting, with one receiving an oral presentation [1] - The company's original first-in-class drug, Orebatinib (Nailike®), has been selected for the ASH meeting for the eighth consecutive year, highlighting its ongoing clinical progress [1] - The original first-in-class drug, Lishatoclax (Lishengtuo®; R&D code: APG-2575), has two clinical advancements selected for the ASH meeting, marking its fourth consecutive year of selection [1] Product Developments - Nailike® is the first third-generation BCR-ABL inhibitor approved in China, with commercialization jointly managed by the company and Innovent Biologics. The company will present the latest data from the global Phase III POLARIS-1 study on Nailike® combined with low-intensity chemotherapy for newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients at the ASH meeting [2] - The company will also update data from a randomized controlled Phase II study on Nailike® for patients with tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia in chronic phase (CML-CP) and data for second-line treatment of non-T315I mutation CML-CP patients [2] - Lishatoclax is a novel oral Bcl-2 selective inhibitor developed by the company, approved in China for adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have undergone at least one systemic treatment including a Bruton tyrosine kinase (BTK) inhibitor. The company will present the latest advancements from a registered Phase II clinical study on Lishatoclax for relapsed/refractory (R/R) CLL/SLL patients [2] Event Information - The 67th ASH Annual Meeting is one of the largest international academic events in the field of hematology, covering research on the etiology and treatment of blood diseases. The event will take place from December 6 to December 9, 2025, in Orlando, Florida, in a hybrid format [3]